Respiratory Motion, Inc. Awarded National Group Breakthrough Technologies Purchasing Contract by Premier

Premier Hospitals now provide Respiratory Motion’s ExSpiron™ Respiratory Monitor to improve patient safety


Waltham, MA – September 18, 2018 – Respiratory Motion, Inc. is announcing the award of a group purchasing agreement as a Breakthrough Technology with Premier Inc., a leading healthcare improvement company.  Premier unites an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers who will now have direct access to Respiratory Motion’s ExSpiron™ , the first and only Minute Ventilation Monitor for all patients. The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier. In response to increasing pressure to improve the safety of patients, especially those requiring opioids, hospitals have sought solutions to meet this growing need. Deemed by Premier to be a significant advancement in monitoring patients’ breathing, the ExSpiron™ was approved through Premier’s Technology Breakthroughs program to give members immediate access to this technology without waiting for the next contracted supplier competitive bidding cycle.  

See the full release here.

Respiratory Motion, Inc. is excited to announce the FDA clearance for the ExSpiron™ 1Xi Minute Ventilation monitor for the use in Pediatric Patients

· Minute Ventilation (MV) is the earliest indicator of insufficient breathing. The ExSpiron is the first and only MV monitor capable of providing continuous, non-invasive measurements for individuals not on a ventilator.

Respiratory Motion, Inc. (Waltham, Massachusetts, USA) reported today that FDA clearance was received for the newest version of its ExSpiron Minute Ventilation (MV) monitoring system on Friday March 16th and announced its plan to launch the new ExSpiron at the Society for Pediatric Anesthesia-American Academy of Pediatrics in Phoenix, March 23-25.

Respiratory failure can occur anywhere in the hospital and early detection can often make the difference between life and death. MV monitoring is the most direct measure of respiratory status, providing the earliest warning of changes in respiratory status. Sufficient time to act is crucial in preventing bad outcomes. Respiratory Motion’s ExSpiron is the first and only continuous Minute Ventilation Monitor that has been cleared for broad use in hospital and ancillary medical settings.

See the full release here.

Respiratory Motion, Inc. and Corestone Biosciences (Beijing) Co., Ltd., have established a Joint Venture Company to deliver monitoring solutions to Chinese health care market and the globe.

Respiratory Motion, Inc. and Corestone Biosciences (Beijing) Co., Ltd., have established a Joint Venture Company to deliver monitoring solutions to Chinese health care market and the globe.

Respiratory Motion, Inc. (Waltham, Massachusetts, USA) the global leader in minute ventilation monitoring and Corestone Biosciences Co., Ltd., an innovative medical device company in anesthesia and analgesia headquartered in Beijing, China have entered into an agreement to form a Joint Venture Company (JV). The JV will offer a new generation of Respiratory Volume Monitors based on Respiratory Motion’s ExSpiron platform, along with other novel critical care solutions for hospital and home markets. The JV will operate out of Zhengzhou in Henan province and through a broad network to deliver its services across China and globally.

See the full release here.

Respiratory Motion, Inc. is excited to announce the launch of the latest ExSpiron™ 1Xi Respiratory Monitor

  • The FDA has cleared the newest version of the non-invasive ExSpironTM Minute Ventilation Monitor which does not require calibration.

  • Minute Ventilation (MV) is the earliest indicator of insufficient breathing, and the ExSpiron is the first and only device to provide accurate MV measurements continuously and non-invasively.

  • This new version of the ExSpiron greatly expands the clinical usefulness of the ExSpiron… now assessing breathing and helping to direct care in seconds, “anytime, anywhere”.

Waltham, Mass. (October 17, 2017) – Respiratory Motion, Inc., announced today its plans to launch the newest version of its ExSpiron 1Xi™ Minute Ventilation (MV) Monitor at the American Society of Anesthesiologists (ASA) in Boston, October 21-25 following recent FDA 510(k) clearance. This new ExSpiron requires no calibration, which greatly expands its range of use.  Physicians, nurses, respiratory therapists, EMT’s and first responders can now easily assess and measure a patients breathing in seconds. 

See the full release here.

Respiratory Motion Receives CE Mark for ExSpiron™

Waltham, MA (May 26, 2016) - Respiratory Motion, Inc. today announced the CE Mark and full market release of ExSpiron™ for clinical use in CE countries, offering clinicians the only Patient Monitor Measuring Minute Ventilation.  

“Clinicians around the world rely on Minute Ventilation (MV) to make decisions on the respiratory status of patients on mechanical ventilators. ExSpiron™ is the only medical device able to provide this measurement in a patient monitor, offering immediate insight into a patients’ respiratory status than what is available in the market today”, stated Jenny Freeman, MD, CEO of Respiratory Motion. “We are excited to bring Minute Ventilation Monitoring to CE countries with the goal of helping clinicians more rapidly detect changes in respiratory status.”

See the full release here.

Member Login
Welcome, (First Name)!

Forgot? Show
Log In
Enter Member Area
My Profile Not a member? Sign up. Log Out